Test whether Qualia Testosterone+ helps raise testosterone in adult men
Official title: The Efficacy of Qualia Testosterone+ on Testosterone Levels: A Triple-Armed Placebo-Controlled Parallel Study
Run by Qualia Life Sciences · NCT07556458 · Data updated 2026-11-12
This study will test if two different Qualia Testosterone+ formulations can raise total testosterone levels in men aged 28–65 with low testosterone compared to placebo.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 28 Years to 65 Years |
| Sex | Men only |
| Enrollment | 75 (estimated) |
| Sponsor | Qualia Life Sciences Industry-sponsored |
| Locations | 1 site (Carlsbad, California) |
| Status | Recruiting |
| Started | May 19, 2026 |
| Main results expected | November 2026 |
| Study ends | November 2026 |
| Registry record updated | October 5, 2026 |
| Trial ID | NCT07556458 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men aged 28–65 with total testosterone ≤500 ng/dL who are willing to take the product daily for 28 days and complete electronic questionnaires.
✕Probably not a fit
Individuals with testosterone levels above the inclusion threshold, those unable to comply with study procedures, or those who experience adverse reactions may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a randomized, double-blind, placebo-controlled trial with three parallel groups to compare two Qualia Testosterone+ formulations against a placebo over 28 days. Approximately 75 participants with total testosterone at or below 500 ng/dL will be assigned equally to each group. Primary outcome is change in total testosterone from baseline to day 28, with secondary outcomes including free testosterone, AMS scores, fatigue, and safety measures. Blood samples are collected at sites, while symptom and safety data are captured electronically at home, with follow-up conducted after the treatment period.
Why it matters
Potential benefit: If successful, participants may experience an increase in testosterone levels and improvement in related symptoms.
How similar studies have gone: Previous studies with similar androgen-supportive supplements have shown variable effects; this trial tests two formulations in a controlled, parallel design.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Provide voluntary, written, informed consent to participate in the study * Agree to provide a valid cell phone number and are willing to receive communications through text * Can read and write English * Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly * Willing to complete questionnaires, records, and diaries associated with the study. * Male participants aged 28-65 * A ≤500 ng/dL Total Testosterone at baseline * Willing and able to visit a local blood draw facility for required blood sample collections * Live within 20 miles of a suitable blood draw facility * Willing to not consume any supplements containing Testosterone or botanicals known to impact hormones starting about 2 weeks prior to the baseline blood test and continuing through the intervention period. Exclusion Criteria: * Known food intolerances/allergy to any ingredients in the product * Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer * Having had a significant cardiovascular event in the past 6 months * Taking MAO inhibitors, SSRIs, blood thinners, or any other psychiatric or neurological medicines * On immunosuppressive therapy * Individuals who were deemed incompatible with the test protocol * Adults lacking capacity to consent * Female * Have Hypogonadism * On Testosterone Replacement Therapy * Taking Gonadotropin-releasing hormone (GnRH) injections or gonadotropins (hCG or FSH)
Where it's running
-
Qualia Life Sciences
Carlsbad, California, United States Recruiting
Study contacts
- Principal investigator: Colin Gardner, PhD — Qualia Life Sciences, LLC
- Study coordinator: Colin Gardner, PhD
- Email: colin@qualialife.com
- Phone: 678-387-7924
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing standard therapy with or without surgery or radiation for metastatic prostate cancer
This study is testing whether adding surgery or radiation to standard treatment helps men with metastatic prostate cancer live longer and feel better compared to just standard treatment alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.